Recent 8-K filings for LBRX

• May 12, 2026, 4:21 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  LB Pharma Q1 net loss $19.1M; cash $365.6M; Phase 3 schizophrenia trial launched

  Net loss of $19.1M in Q1 2026 vs $5.3M in Q1 2025; R&D expenses rose $11.2M to $14.6M.

• March 26, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  LB Pharmaceuticals reports Q4 net loss $11.5M; cash $295.2M; advances LB-102 into Phase 3

  Positive Phase 2 (NOVA-1) results for LB-102 in acute schizophrenia met primary endpoint; Phase 3 NOVA-2 initiated March 2026 with data expected H2 2027.

• February 5, 2026, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 7.01item 8.01item 9.01 ◈ Equity Issuances ×2◈ Material Agreements

  LB Pharmaceuticals raises $100M in private placement; Phase 2 MDD trial for LB-102 starts early 2027

  Gross proceeds ~$100M from sale of 3.31M shares and 1.42M pre-funded warrants at $21.17/share.

• November 12, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 8.01item 9.01

  LB Pharmaceuticals appoints Kaya Pai Panandiker as Chief Commercial Officer

  Effective Nov 10, 2025; Panandiker previously CCO at Neumora Therapeutics.

• November 6, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  LB Pharmaceuticals Reports Q3 2025 Results and Provides Trial Updates

  Net loss narrowed to $3.6M in Q3 2025 from $14.2M in Q3 2024.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.55 · Most common event leadership

2 positive 1 negative 8 neutral

source · LBRX on sec.gov